TVTX Q1 2019 Earnings — Travere Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TVTXTravere Therapeutics, Inc.

$3B

Q1 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$40M+3.0% YoY

Gross Profit

$39M97.4% margin

Operating Income

-$38M-96.6% margin

Net Income

-$41M-103.6% margin

EPS (Diluted)

$-0.99

QoQ Revenue Growth

-9.6%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$24M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$668M

Total Liabilities

$382M

Stockholders' Equity

$286M

Cash & Equivalents

$70M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$40M	$38M	+3.0%
Gross Profit	$39M	$37M	+4.7%
Operating Income	-$38M	-$18M	-113.4%
Net Income	-$41M	-$18M	-123.0%

Revenue Segments

Thiola License

$21M54%

Bile Acid Products

$18M46%